Braden Michael Leonard

Braden Michael Leonard (chief executive) discloses dealings in 14 companies, chiefly ASTROTECH Corp, Adverum Biotechnologies, Inc. and Aclaris Therapeutics, Inc. We count 76 filings; the first trade dates from 12 April 2022 and the latest from 2 October 2026.

Market trades split into 59 purchases (€16.4M) and 15 sales (€21.9M). Netting one side against the other leaves €5.5M of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2026, the count stands at 2 purchases and 1 sale.

Half of the purchases are above €87k and half below. On 1 out of 57 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. After 16 purchases with a full 90-day history, the hit rate stands at 56% and the median 90-day move at +6.7%. These figures describe past trades and do not predict future prices.

The newest entry dates from 5 October 2026: an open-market purchase of €711k, in Outset Medical, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.